These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20150371)

  • 41. Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
    Phuphanich S; Baker SD; Grossman SA; Carson KA; Gilbert MR; Fisher JD; Carducci MA
    Neuro Oncol; 2005 Apr; 7(2):177-82. PubMed ID: 15831235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase I study of weekly topotecan combined to concurrent external cranial irradiation in adults with glioblastoma multiforme of the brain.
    Varveris H; Petinelli E; Stratakis J; Mazonakis M
    Oncol Rep; 2008 Feb; 19(2):447-55. PubMed ID: 18202794
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
    Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
    J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
    Peereboom DM; Shepard DR; Ahluwalia MS; Brewer CJ; Agarwal N; Stevens GH; Suh JH; Toms SA; Vogelbaum MA; Weil RJ; Elson P; Barnett GH
    J Neurooncol; 2010 May; 98(1):93-9. PubMed ID: 19960228
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Friedman AH; Herndon JE; Marcello J; Norfleet JA; McLendon RE; Sampson JH; Friedman HS
    J Neurooncol; 2010 Jan; 96(2):219-30. PubMed ID: 19562254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers.
    Hughes AN; O'Brien ME; Petty WJ; Chick JB; Rankin E; Woll PJ; Dunlop D; Nicolson M; Boinpally R; Wolf J; Price A
    J Clin Oncol; 2009 Mar; 27(8):1220-6. PubMed ID: 19164205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reverse swing-M, phase 1 study of repurposing mebendazole in recurrent high-grade glioma.
    Patil VM; Bhelekar A; Menon N; Bhattacharjee A; Simha V; Abhinav R; Abhyankar A; Sridhar E; Mahajan A; Puranik AD; Purandare N; Janu A; Ahuja A; Krishnatry R; Gupta T; Jalali R
    Cancer Med; 2020 Jul; 9(13):4676-4685. PubMed ID: 32400117
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
    Kaley TJ; Panageas KS; Pentsova EI; Mellinghoff IK; Nolan C; Gavrilovic I; DeAngelis LM; Abrey LE; Holland EC; Omuro A; Lacouture ME; Ludwig E; Lassman AB
    Ann Clin Transl Neurol; 2020 Apr; 7(4):429-436. PubMed ID: 32293798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
    Murakami H; Tamura T; Takahashi T; Nokihara H; Naito T; Nakamura Y; Nishio K; Seki Y; Sarashina A; Shahidi M; Yamamoto N
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):891-9. PubMed ID: 22071596
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma.
    Phuphanich S; Supko JG; Carson KA; Grossman SA; Burt Nabors L; Mikkelsen T; Lesser G; Rosenfeld S; Desideri S; Olson JJ
    J Neurooncol; 2010 Oct; 100(1):95-103. PubMed ID: 20213332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas.
    Rudek MA; New P; Mikkelsen T; Phuphanich S; Alavi JB; Nabors LB; Piantadosi S; Fisher JD; Grossman SA
    J Neurooncol; 2011 Nov; 105(2):375-81. PubMed ID: 21547395
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
    Geoerger B; Hargrave D; Thomas F; Ndiaye A; Frappaz D; Andreiuolo F; Varlet P; Aerts I; Riccardi R; Jaspan T; Chatelut E; Le Deley MC; Paoletti X; Saint-Rose C; Leblond P; Morland B; Gentet JC; Méresse V; Vassal G;
    Neuro Oncol; 2011 Jan; 13(1):109-18. PubMed ID: 20974795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.
    Nghiemphu PL; Ebiana VA; Wen P; Gilbert M; Abrey LE; Lieberman F; DeAngelis LM; Robins HI; Yung WKA; Chang S; Drappatz J; Mehta MP; Levin VA; Aldape K; Dancey JE; Wright JJ; Prados M; Kuhn J; Cloughesy TF
    J Neurooncol; 2018 Jan; 136(1):79-86. PubMed ID: 28988377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas.
    Kreisl TN; Kotliarova S; Butman JA; Albert PS; Kim L; Musib L; Thornton D; Fine HA
    Neuro Oncol; 2010 Feb; 12(2):181-9. PubMed ID: 20150385
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
    Geyer JR; Stewart CF; Kocak M; Broniscer A; Phillips P; Douglas JG; Blaney SM; Packer RJ; Gururangan S; Banerjee A; Kieran MW; Kun LE; Gilbertson RJ; Boyett JM
    Eur J Cancer; 2010 Dec; 46(18):3287-93. PubMed ID: 20708924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
    Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
    Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report.
    Pollack IF; Jakacki RI; Blaney SM; Hancock ML; Kieran MW; Phillips P; Kun LE; Friedman H; Packer R; Banerjee A; Geyer JR; Goldman S; Poussaint TY; Krasin MJ; Wang Y; Hayes M; Murgo A; Weiner S; Boyett JM
    Neuro Oncol; 2007 Apr; 9(2):145-60. PubMed ID: 17293590
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma.
    Patel S; DiBiase S; Meisenberg B; Flannery T; Patel A; Dhople A; Cheston S; Amin P
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):739-42. PubMed ID: 21353747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.
    Gilbert MR; Supko JG; Batchelor T; Lesser G; Fisher JD; Piantadosi S; Grossman S
    Clin Cancer Res; 2003 Aug; 9(8):2940-9. PubMed ID: 12912940
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
    D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
    Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.